{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:50:33Z","timestamp":1792788633628,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T00:00:00Z","timestamp":1747526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.euo.2025.05.006","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T23:43:02Z","timestamp":1748475782000},"page":"1406-1415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Influence of Concomitant Androgen Deprivation Therapy and Its Duration for Salvage Radiation After Radical Prostatectomy: A Systematic Review and Network Meta-analysis According to Published Data"],"prefix":"10.1016","volume":"8","author":[{"given":"Quynh Chi","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Siech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Hoeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Preisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Graefen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian C.","family":"Kriegmair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix K.H.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.05.006_b0005","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1007\/s11845-023-03356-z","article-title":"Radiotherapy after radical prostatectomy for prostate cancer: clinical outcomes and factors influencing biochemical recurrence","volume":"192","author":"Fukuda","year":"2023","journal-title":"Ir J Med Sci"},{"key":"10.1016\/j.euo.2025.05.006_b0010","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000481438","article-title":"Management of biochemical recurrence after primary curative treatment for prostate cancer: a review","volume":"100","author":"Artibani","year":"2018","journal-title":"Urol Int"},{"key":"10.1016\/j.euo.2025.05.006_b0015","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/JU.0000000000003891","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part II: treatment delivery for non-metastatic biochemical recurrence after primary radical prostatectomy","volume":"211","author":"Morgan","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.05.006_b0020","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2014.03.011","article-title":"Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96\u201302\/AUO AP 09\/95 trial","volume":"66","author":"Wiegel","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.05.006_b0025","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000536609","article-title":"Why do men reject adjuvant radiotherapy following radical prostatectomy?","volume":"108","author":"Sigg","year":"2024","journal-title":"A systematic survey. Urol Int"},{"key":"10.1016\/j.euo.2025.05.006_b0030","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.05.006_b0035","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/S0140-6736(24)00548-8","article-title":"Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial","volume":"403","author":"Parker","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.05.006_b0040","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","article-title":"Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial","volume":"20","author":"Carrie","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.05.006_b0045","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.05.006_b0050","unstructured":"UroToday. ESMO 2022: Duration of Androgen Suppression with Post-Operative Radiotherapy (DADSPORT): a collaborative meta-analysis of aggregate data. https:\/\/www.urotoday.com\/conference-highlights\/esmo-2022\/esmo-2022-prostate-cancer\/139430-esmo-2022-duration-of-androgen-suppression-with-post-operative-radiotherapy-dadsport-a-collaborative-meta-analysis-of-aggregate-data.html."},{"key":"10.1016\/j.euo.2025.05.006_b0055","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.eururo.2024.07.026","article-title":"Randomised trial of no, short-term, or long-term androgen deprivation therapy with postoperative radiotherapy after radical prostatectomy: results from the three-way comparison of RADICALS-HD (NCT00541047)","volume":"86","author":"Parker","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.05.006_b0060","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(24)00549-X","article-title":"Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial","volume":"403","author":"Parker","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.05.006_b0065","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.euo.2025.05.006_b0070","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.euo.2025.05.006_b0075","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.euo.2025.05.006_b0080","doi-asserted-by":"crossref","first-page":"S1428","DOI":"10.1016\/j.annonc.2022.08.067","article-title":"LBA64 Duration of androgen suppression with post-operative radiotherapy (DADSPORT): A collaborative meta-analysis of aggregate data","volume":"33","author":"Burdett","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.05.006_b0085","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"Lancet (Lond Engl)"},{"key":"10.1016\/j.euo.2025.05.006_b0090","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.euf.2023.03.024","article-title":"Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer: updated network meta-analysis stratified by disease volume","volume":"9","author":"Hoeh","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.05.006_b0095","doi-asserted-by":"crossref","unstructured":"Hoeh B, Wenzel M, Tian Z, et al. Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: an updated network meta-analysis including ARANOTE data. Eur Urol Focus. In press. https:\/\/doi.org\/10.1016\/j.euf.2024.11.004.","DOI":"10.1016\/j.euf.2024.11.004"},{"key":"10.1016\/j.euo.2025.05.006_b0100","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.euf.2022.08.007","article-title":"Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: a systematic review and network meta-analysis","volume":"9","author":"Mandel","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.05.006_b0105","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41391-021-00395-4","article-title":"Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis","volume":"25","author":"Wenzel","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.05.006_b0110","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.euf.2021.04.003","article-title":"Overall survival after systemic treatment in high-volume versus low-volume metastatic hormone-sensitive prostate cancer: systematic review and network meta-analysis","volume":"8","author":"Wenzel","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.05.006_b0115","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2025.05.006_b0120","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.euo.2025.05.006_b0125","first-page":"285","article-title":"Automating network meta-analysis. Res Synth","volume":"3","author":"van Valkenhoef","year":"2012","journal-title":"Methods"},{"key":"10.1016\/j.euo.2025.05.006_b0130","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1471-2288-10-54","article-title":"Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial","volume":"10","author":"Woods","year":"2010","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.euo.2025.05.006_b0135","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.euo.2025.05.006_b0140","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.euo.2025.05.006_b0145","unstructured":"R: The R project for statistical computing. https:\/\/www.r-project.org\/."},{"key":"10.1016\/j.euo.2025.05.006_b0150","doi-asserted-by":"crossref","first-page":"81","DOI":"10.5980\/jpnjurol.112.81","article-title":"Adverse effects of androgen deprivation therapy on patients with prostate cancer and its effect on overall survival","volume":"112","author":"Shimabukuro","year":"2021","journal-title":"Jpn J Urol"},{"key":"10.1016\/j.euo.2025.05.006_b0155","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.05.006_b0160","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jamaoncol.2015.4917","article-title":"Comparison of gonadotropin-releasing hormone agonists and orchiectomy: effects of androgen-deprivation therapy","volume":"2","author":"Sun","year":"2016","journal-title":"JAMA Oncol"},{"issue":"5 Pt 1","key":"10.1016\/j.euo.2025.05.006_b0165","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1097\/01.ju.0000140159.94703.80","article-title":"Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years","volume":"172","author":"Wirth","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.05.006_b0170","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jsxm.2019.03.273","article-title":"Testosterone recovery profiles after cessation of androgen deprivation therapy for prostate cancer","volume":"16","author":"Nascimento","year":"2019","journal-title":"J Sex Med"},{"key":"10.1016\/j.euo.2025.05.006_b0175","doi-asserted-by":"crossref","first-page":"65.e1","DOI":"10.1016\/j.urolonc.2024.08.005","article-title":"Testosterone recovery after androgen deprivation therapy","volume":"43","author":"Ho","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.05.006_b0180","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.05.006_b0185","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1200\/JCO.2017.76.4126","article-title":"Phase III intergroup trial of adjuvant androgen deprivation with or without mitoxantrone plus prednisone in patients with high-risk prostate cancer after radical prostatectomy: SWOG S9921","volume":"36","author":"Hussain","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T17:34:13Z","timestamp":1766511253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125001312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2588931125001312"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.05.006","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of Concomitant Androgen Deprivation Therapy and Its Duration for Salvage Radiation After Radical Prostatectomy: A Systematic Review and Network Meta-analysis According to Published Data","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}